A Holistic Approach to Treatment of Rosacea During Pregnancy: A Systematic Review
Main Article Content
Keywords
Rosacea, Pregnancy, Osteopathic Manipulative Treatment, Rosacea Treatment, Rosacea-associated Edema
Abstract
Background: Rosacea is a chronic inflammatory skin condition that is commonly exacerbated during pregnancy. Many patients suffer from emotional distress as a result of their rosacea, but the standard treatment options can cause harm to a developing fetus.
Methods: A systematic review was conducted on PubMed and EMBASE using the keywords “rosacea,” “pregnancy,” “treatment,” “holistic,” “edema, and “osteopathic manipulative treatment” (OMT). 113 papers were extracted and screened to determine eligibility based on inclusion criteria: primary sources, rosacea diagnosis, and documented treatment. Those that did not meet criteria were excluded and 20 papers remained for this review.
Results: The 20 included sources had a total of 230 participants who presented with rosacea fulminans (RF) or rosacea-associated edema. Treatment options included antibiotics, steroids, topical antiseptic, wet compresses, and OMT. Of the patients who were pregnant, complications included ocular perforation, corneal transplant, fetal arrhythmia, oligohydramnios, and intrauterine death. Some patients even elected for termination of pregnancy due to rosacea-related anxiety and depression.
Discussion: The emotional distress that these patients faced and physical harm to their babies confirms the need for a holistic approach to treating rosacea during pregnancy. An expected limitation is that some of these complications may be the result of chance, while others may have been due to medications used. It was concluded that pregnancy-safe antibiotics or low-dose topical steroids in combination with OMT or holistic management would be the most effective approach.
References
2. Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501-1510.
3. Fisher GW, Travers JB, Rohan CA. Rosacea pathogenesis and therapeutics: current treatments and a look at future targets. Front Med. 2023;10:1292722.
4. Tyler KH. Dermatologic therapy in pregnancy. Clin Obstet Gynecol. 2015;58(1):112-118.
5. Seffinger M. Foundations of Osteopathic Medicine. 4th ed. Lippincott Williams and Wilkins; 2019.
6. Kutlay S, Ozdemir EC, Pala Z, Ozen S, Sanli H. Complete decongestive therapy is an option for the treatment of Rosacea lymphedema (Morbihan disease): Two cases. Phys Ther. 2019;99(4):406-410.
7. Çinar GN, Özgül S, Nakip G, et al. Complex decongestive therapy in the physical therapist management of Rosacea-related edema (Morbus Morbihan Syndrome): A case report with a new approach. Phys Ther. 2021;101(9). doi:10.1093/ptj/pzab133
8. Jay R, Rodger J. Resolution of rosacea-associated persistent facial edema with osteopathic manipulative treatment. JAAD Case Rep. 2022;28:83-86.
9. Heisig M, Reich A. Psychosocial aspects of rosacea with a focus on anxiety and depression. Clin Cosmet Investig Dermatol. 2018;11:103-107.
10. Markou AG, Alessandrini V, Muray JM, Begon E, Fysekidis M. Rosacea fulminans during pregnancy. Clin Exp Obstet Gynecol. 2017;44(1):157-159.
11. Fuentelsaz V, Ara M, Corredera C, Lezcano V, Juberias P, Carapeto FJ. Rosacea fulminans in pregnancy: successful treatment with azithromycin. Clin Exp Dermatol. 2011;36(6):674-676.
12. Demir O, Tas IS, Gunay B, Gungor Ugurlucan F. A rare dermatologic disease in pregnancy: Rosacea fulminans- case report and review of the literature. Open Access Maced J Med Sci. 2018;6(8):1438-1441.
13. Lewis VJ, Holme SA, Wright A, Anstey AV. Rosacea fulminans in pregnancy. Br J Dermatol. 2004;151(4):917-919.
14. Garayar Cantero M, Garabito Solovera E, Aguado García Á, Valtueña J, Ruiz Sánchez D, Manchado López P. Use of permethrin in the treatment of rosacea fulminans during pregnancy: One case report. Dermatol Ther. 2020;33(3). doi:10.1111/dth.13436
15. Ferahbas A, Utas S, Mistik S, Uksal U, Peker D. Rosacea fulminans in pregnancy. Am J Clin Dermatol. 2006;7(2):141-144.
16. Jarrett R, Gonsalves R, Anstey AV. Differing obstetric outcomes of rosacea fulminans in pregnancy: report of three cases with review of pathogenesis and management. Clin Exp Dermatol. 2010;35(8):888-891.
17. Haenen CCP, Kouwenhoven STP, van Doorn R. Rosacea fulminans in pregnancy. Ned Tijdschr Geneeskd. 2015;159:A8334.
18. Ranpariya V. Unexpected complications: A case of Rosacea fulminans in pregnancy. Cutis. 2021;108(1). doi:10.12788/cutis.0290
19. Cisse M, Maruani A, Bré C, Domart P, Jonville-Bera AP, Machet L. Rosacée fulminante au début d’une grossesse par fécondation in vitro et transfert d’embryons (FIVETE). Ann Dermatol Venereol. 2008;135(10):675-678.
20. Silva FA de M e., Bonassi M, Steiner D, Cunha TVR da. Rosacea fulminans in pregnancy with ocular perforation. J Dtsch Dermatol Ges. 2011;9(7):542-543.
21. Korenevska A, Morozova E, Kayumova L, Pinegin V, Ostretsova M. Influence of a patient’s somatic pathology on skin manifestations encountered by a cosmetologist. Clin Ter. 2023;174(5):404-411.
22. Wang B, Yuan X, Huang X, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol. 2021;84(2):543-545.
23. Thomas S, Luke JD. Ivermectin topical. J Dermatol Nurses Assoc. 2020;12(2):94-96.
24. Patel VM, Schwartz RA, Lambert WC. Topical antibiotics in pregnancy: A review of safety profiles. Dermatol Ther. Published online May 16, 2019:e12951.
25. Bhatia N, Ahmadyar M, Hansra H, Rosso D, Baldwin J, Daniels H. Cutaneous tolerability of novel topical minocycline gel for the treatment of rosacea. J Clin Aesthet Dermatol. 2018;11(5):S29-S30.
26. Shangraw S. Papulopustular rosacea improvement in pregnancy: A case report. J Am Acad Dermatol. 2017;76(6). doi:10.1016/j.jaad.2017.04.730
27. Zauli S, Mantovani L, Ricci M, Sarno O, Bettoli V. Rosacea fulminans: Personal experience. J Am Acad Dermatol. 2011;64(2):AB18.
28. Thiboutot DM. Acne rosacea. Am Fam Physician. 1994;50(8):1691-1697, 1701-1702.
29. Hensel KL, Carnes MS, Stoll ST. Pregnancy Research on Osteopathic Manipulation Optimizing Treatment Effects: The PROMOTE study protocol. J Am Osteopath Assoc. 2016;116(11):716-724.
30. Organization of Teratology Information Specialists (OTIS); 1994-. Amoxicillin and Clavulanic Acid.; 2022.
31. Putra IB, Jusuf NK, Dewi NK. Skin changes and safety profile of topical products during pregnancy. J Clin Aesthet Dermatol. 2022;15(2):49-57.
32. Organization of Teratology Information Specialists (OTIS); 1994-. Topical Acne Treatments.; 2021.
33. DailyMed - betamethasone dipropionate cream. National Institutes of Health.
34. Lockshin MD, Sammaritano LR. Corticosteroids during pregnancy. Scand J Rheumatol. 1998;27(sup107):136-138.
35. McMullan P, Yaghi M, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: An Update - Part I: Pregnancy. J Am Acad Dermatol. Published online January 25, 2024. doi:10.1016/j.jaad.2023.10.072
36. Topical acne treatments. In: Mother To Baby | Fact Sheets. Mother To Baby | Fact Sheets Organization of Teratology Information Specialists. Published online 1994.
37. Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol. 2013;149(11):1274-1280.
38. Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. JAMA Dermatol. 2021;157(7):788-795.
39. Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43(3):489-502.
40. ACOG committee opinion no. 776: Immune modulating therapies in pregnancy and lactation. Obstet Gynecol. 2019;133(4):e287-e295.
41. Schander A, Downey HF, Hodge LM. Lymphatic pump manipulation mobilizes inflammatory mediators into lymphatic circulation. Exp Biol Med . 2012;237(1):58-63.
42. Zauli S, Mantovani L, Ricci M, Sarno O, Bettoli V. Rosacea fulminans: Personal experience. J Am Acad Dermatol. 2011;64(2).
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.